

NeurAxon, Inc. to Present at 10th Annual BIO CEO & Investor Conference

WALTHAM, MA. February 7, 2008 -- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer will present at the 10th Annual BIO CEO & Investor Conference to be held February 11-13, 2008 in New York, New York.

The NeurAxon presentation will begin at 2:00 pm Eastern Time on Tuesday, February 12, 2008 in the Library room at the Waldorf=Astoria Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT antagonist which is entering Phase 2 trials for acute migraine.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:

Chris Erdman
MacDougall Biomedical Communications
617.686.1718